936.9000 -7.80 (-0.83%)
NSE Sep 12, 2025 15:31 PM
Volume: 33,281
 

936.90
-0.83%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences Ltd. is trading below all available SMAs
More from Alivus Life Sciences Ltd.
Recommended